Home » News » Ethics/Regulatory » FDA approves WuXi’s manufacture of ibalizumab in China for use under a U.S. IND

FDA approves WuXi’s manufacture of ibalizumab in China for use under a U.S. IND

Wednesday, May 7, 2014

The FDA has approved the first batch of the ibalizumab (TMB-355) drug substance and sterile drug product, manufactured at WuXi PharmaTech‘s biologics facilities and developed by TaiMed Biologics for the treatment of HIV/AIDS infection. 

This is the first reported FDA approval of a sterile biologics product manufactured in China for use under a U.S. IND. WuXi sais it marks an important milestone in its investment to expedite global development of innovative biologics.

WuXi is a pharmaceutical, biotechnology and medical device R&D services company, with operations in China and the U.S. TaiMed Biologics is a publicly held Taiwanese biotechnology company. Ibalizumab is a humanized monoclonal antibody and a member of an emerging class of HIV therapies known as viral-entry inhibitors. 

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!